Results 41 to 50 of about 240,252 (146)

Host modulation by therapeutic agents

Journal of Pharmacy and Bioallied Sciences, 2012
Periodontal disease susceptible group present advanced periodontal breakdown even though they achieve a high standard of oral hygiene. Various destructive enzymes and inflammatory mediators are involved in destruction.
Sugumari Elavarasu, Santhosh Sekar, Thamaraiselvan Murugan   +2 more
doaj   +1 more source

The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation

Mediators of Inflammation, 1998
Lipopolysaccharide is an inflammatory agent and interleukin-1 is a cytokine. Their pro-inflammatory effects may be mediated by prostanoids produced by inducible cyclooxygenase-2.
W. E. Longo, L. J. Damore, J. E. Mazuski, G. S. Smith, N. Panesar, D. L. Kaminski   +5 more
doaj   +1 more source

Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque

Pharmaceuticals, 2022
Atherosclerosis is a disorder in which, in addition to high cholesterol levels, several plasma factors play a significant role in its development. Among these cytokines and molecules are interleukin 6 (IL-6), interleukin 18 (IL-18), tumor necrosis factor
Marcin Basiak, Michal Kosowski, Marcin Hachula, Boguslaw Okopien   +3 more
doaj   +1 more source

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Objective: This review was performed to compare the efficacy and safety among hospitalized patients with COVID-19 who received baricitinib and those who received tocilizumab independently with placebo or the standard of care (SOC).Methods: Relevant ...
Jerin Jose Cherian, Madhavi Eerike, Bhavani Shankara Bagepally, Saibal Das, Saibal Das, Samiran Panda   +5 more
doaj   +1 more source

A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs

Frontiers in Pharmacology, 2020
For the initial phase of pandemic of coronavirus disease 2019 (COVID-19), repurposing drugs that in vitro inhibit severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been attempted with overlooked or overestimated efficacy owing to limited ...
Po-Lin Chen, Po-Lin Chen, Po-Lin Chen, Nan-Yao Lee, Nan-Yao Lee, Cong-Tat Cia, Cong-Tat Cia, Wen-Chien Ko, Wen-Chien Ko, Po-Ren Hsueh   +9 more
doaj   +1 more source

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan

Современная ревматология
Objective: to assess the efficacy and safety of olokizumab (OKZ) in routine clinical practice in patients with rheumatoid arthritis (RA) in Kazakhstan.Material and methods.
G. A. Togizbayev, D. I. Parpiyeva, D. A. Maksot   +2 more
doaj   +1 more source

Psoriatic arthritis successfully treated with second-line anti-interleukin-6 treatment: a case report and review of the literature 

Journal of Medical Case Reports, 2022
Background Psoriatic arthritis treatment with antitumor necrosis factor has been shown to reduce disease activity. Nonetheless, more than 30% of patients do not achieve a sufficient response to tumor necrosis factor blockers.
Tatsuhiko Kutsuna, Kazunori Hino, Hitoshi Hasegawa, Kunihiko Watamori, Teruki Kidani, Hiroshi Imai, Hiromasa Miura   +6 more
doaj   +1 more source

Achievement of intermediate treatment targets for Still’s disease under tocilizumab treatment: a post-hoc analysis of the phase III trial

Immunological Medicine
To evaluate the intermediate treatment targets for Still’s disease proposed by EULAR/PReS recently, we conducted this post-hoc analysis of the Phase III trial of tocilizumab and its long-term extension to assess the achievement probability of these ...
Koji Suzuki, Hideto Kameda, Kei Ikeda, Tomonori Ishii, Kosaku Murakami, Hyota Takamatsu, Yoshiya Tanaka, Takayuki Abe, Tsutomu Takeuchi, Yuko Kaneko   +9 more
doaj   +1 more source

Tocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report

SAGE Open Medical Case Reports
Psoriasis is an immune-mediated inflammatory disorder with a strong genetic predisposition. However, in some cases, it can emerge as an adverse effect of biologic therapy, particularly interleukin-6 inhibitors such as tocilizumab.
Rahul Yedpallikar Rajesh, Pavisankar Biju Seena, Eka Nakhutsrishvili, Tejasri Akkineni, Aasim Akthar Ahmed, Tarun Kumar Suvvari, Vimal Thomas, Tejinder Singh   +7 more
doaj   +1 more source

Interleukin-1β promotes interleulin-6 expression via ERK1/2 signaling pathway in canine dermal fibroblasts.

PLoS ONE, 2019
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in the regulation of the immune response and inflammation. In this study, we investigated effect of the proinflammatory cytokine interleukin-1β (IL-1β) on IL-6 expression in canine dermal ...
Nanako Kitanaka, Rei Nakano, Kanae Sugiura, Taku Kitanaka, Shinichi Namba, Tadayoshi Konno, Tomohiro Nakayama, Hiroshi Sugiya   +7 more
doaj   +1 more source